Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy

Baxter, DE orcid.org/0000-0001-8830-6802, Kim, B, Hanby, AM orcid.org/0000-0001-7966-1570 et al. (3 more authors) (2018) Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy. Clinical Breast Cancer, 18 (6). pp. 481-488. ISSN 1526-8209

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 Elsevier Inc. This is an author produced version of a paper published in Clinical Breast Cancer. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: ABC transporters; Chemoresistance; Epirubicin; Induced therapy resistance; Multiple drug resistance
Dates:
  • Published: December 2018
  • Accepted: 3 July 2018
  • Published (online): 6 July 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Jul 2018 11:37
Last Modified: 06 Jul 2019 00:43
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.clbc.2018.07.002

Share / Export

Statistics